National Bank of Canada’s Aurinia Pharmaceuticals AUPH Stock Holding History

National Bank of Canada’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.2K	Buy	686 +10	+1%	+$146	﹤0.01%	2330
2025 Q4	$10.8K	Buy	676 +9	+1%	+$128	﹤0.01%	2297
2025 Q3	$7.37K	Sell	667 -23	-3%	-$251	﹤0.01%	2388
2025 Q2	$5.85K	Hold	690	–	–	﹤0.01%	2458
2025 Q1	$5.54K	Buy	690 +400	+138%	+$3.24K	﹤0.01%	2367
2024 Q4	$2.6K	Hold	290	–	–	﹤0.01%	2549
2024 Q3	$2.13K	Sell	290 -216	-43%	-$1.34K	﹤0.01%	2346
2024 Q2	$2.77K	Hold	506	–	–	﹤0.01%	2376
2024 Q1	$2.54K	Sell	506 -630	-55%	-$4.27K	﹤0.01%	2418
2023 Q4	$9.91K	Hold	1,136	–	–	﹤0.01%	2170
2023 Q3	$8.38K	Hold	1,136	–	–	﹤0.01%	2237
2023 Q2	$11K	Buy	1,136 +560	+97%	+$5.81K	﹤0.01%	2154
2023 Q1	$6.31K	Buy	576 +40	+7%	+$352	﹤0.01%	2243
2022 Q4	$2.31K	Buy	536 +153	+40%	+$888	﹤0.01%	2464
2022 Q3	$3K	Hold	383	–	–	﹤0.01%	2424
2022 Q2	$4K	Hold	383	–	–	﹤0.01%	2452
2022 Q1	$5K	Hold	383	–	–	﹤0.01%	2534
2021 Q4	$9K	Buy	+383	New	+$9.07K	﹤0.01%	2377

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

National Bank of Canada's AUPH Position: Q1 2026 in Review

National Bank of Canada increased its Aurinia Pharmaceuticals (AUPH) stake by 1.5% in Q1 2026, buying an estimated $146 and bringing the position to 686 shares worth $10.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2330.

National Bank of Canada first reported a position in AUPH in Q4 2021 and has held it in 18 quarters since. The position peaked at $11K in Q2 2023. 259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.

National Bank of Canada held 686 shares of Aurinia Pharmaceuticals worth $10.2K as of Q1 2026.
National Bank of Canada bought 10 Aurinia Pharmaceuticals shares in Q1 2026, an estimated $146.
Aurinia Pharmaceuticals made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #2330 holding.
National Bank of Canada first reported a position in Aurinia Pharmaceuticals in Q4 2021 and has held it in 18 quarters since.
National Bank of Canada's Aurinia Pharmaceuticals position peaked at $11K in Q2 2023.
259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.